Comparative Pharmacology
Head-to-head clinical analysis: CABOMETYX versus LENVIMA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CABOMETYX versus LENVIMA.
CABOMETYX vs LENVIMA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cabozantinib is a small molecule inhibitor of multiple receptor tyrosine kinases, including MET, VEGFR2, RET, AXL, KIT, and FLT3. It inhibits tumor growth, angiogenesis, and metastasis by blocking these pathways.
Lenvatinib is a multikinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR1, VEGFR2, VEGFR3), fibroblast growth factor receptors (FGFR1, FGFR2, FGFR3, FGFR4), platelet-derived growth factor receptor alpha (PDGFRα), KIT, and RET. It inhibits angiogenesis, tumor growth, and progression by blocking these receptor tyrosine kinases.
60 mg orally once daily for the first 21 days of a 21-day cycle, with or without food, for renal cell carcinoma; for hepatocellular carcinoma, 60 mg orally once daily.
24 mg orally once daily for differentiated thyroid carcinoma; 18 mg orally once daily plus everolimus 5 mg orally once daily for renal cell carcinoma; 12 mg orally once daily plus pembrolizumab 200 mg intravenously every 3 weeks for endometrial carcinoma; 8 mg orally once daily (or 10 mg for patients with body weight ≥60 kg) plus pembrolizumab 200 mg intravenously every 3 weeks for hepatocellular carcinoma.
None Documented
None Documented
Terminal half-life approximately 99 hours (range 80–120 h). Supports once-daily dosing with steady-state achieved within 15 days.
Terminal elimination half-life is approximately 28 hours, supporting once-daily dosing.
Primarily fecal (54%) with minimal renal excretion (27% unchanged drug; <10% as metabolites). Biliary excretion contributes to fecal elimination.
Approximately 71% of the dose is excreted in feces (34% as unchanged drug) and 25% in urine (0.4% as unchanged).
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor